CAR T cell News and Research

RSS

Enhanced CAR T-cell therapy may improve treatment options for patients with B-cell blood cancers

Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers.

13 Oct 2026

Review highlights emerging treatments for glioblastoma multiforme

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026)."

25 Sep 2026

CAR T-cell therapy enables safe pregnancies in autoimmune patients

Autoimmune diseases such as systemic lupus erythematosus mainly affect young women, often in a phase of their lives where they would like to have children.

22 Sep 2026

CRISPR activation library uncovers gene driving lymphoma growth and resistance

Researchers have uncovered a previously unknown gene causing resistance to a leading blood cancer drug and several genes that accelerate lymphoma growth by using a powerful new CRISPR activation library.

18 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

UCLA researchers develop scalable TCR therapy for solid tumors

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell.

8 Sep 2026

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

Discover how LumiPore improves intracellular delivery with gentle, high-efficiency transfection for drug discovery and cell therapy research.

From Trince 8 Sep 2026

New optical imaging reveals metabolic activity of individual immune cells

A routine blood sample contains a diverse collection of immune cells that can reveal important clues about health and disease.

2 Sep 2026

CAR T-cell therapy successfully reverses severe rheumatoid arthritis

Immunotherapies such as CAR T-cell therapy are used primarily to treat cancer. In the future, these patient-specific therapies, manufactured from patients' own immune cells, could also help cure autoimmune diseases.

27 Aug 2026

Gene removal makes engineered immune cells more effective against osteosarcoma

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma.

25 Aug 2026

Red blood cells inspire next-generation therapeutic nanocarriers

Red blood cells serve as the foundation for nanocarriers that show promise in a new study as effective and efficient vehicles for gene therapy, tumor targeting and other medical treatments.

19 Aug 2026

UC Irvine researchers develop framework to make CAR T-cell therapy safer

CAR T-cell therapy has transformed cancer care, offering new hope to patients with aggressive blood cancers who once had few treatment options.

18 Aug 2026

Engineered red blood cell vesicles improve gene therapy delivery

Red blood cells serve as the foundation for nanocarriers that show promise in a new study as effective and efficient vehicles for gene therapy, tumor targeting and other medical treatments.

17 Aug 2026

Researchers identify genes that hinder CRISPR editing efficiency

Like a delivery driver navigating crowded city streets, a gene-therapy-toting lipid nanoparticle faces a gauntlet of potential detours on its journey toward a cell's nucleus.

13 Aug 2026

Genetic tool turns soft cancer cells into immune targets

Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a remarkable genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of tumors.

11 Aug 2026

Inherited genetics can influence safety and success of CAR-T cell therapy

Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma.

24 Jul 2026

Off-the-shelf CAR T therapy targets treatment-resistant systemic sclerosis

Today at ISSCR 2026, new preliminary clinical data was presented evaluating an induced pluripotent stem cell (iPSC)-derived CAR T-cell therapy for patients with treatment-resistant systemic sclerosis, a rare autoimmune disease with high mortality.

9 Jul 2026

New analysis reveals biological features of treatment-resistant aggressive lymphoma

Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized.

3 Jul 2026

Engineered CAR T cells show promise against myeloproliferative neoplasms

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, in new research led by UCL and University of Oxford researchers.

1 Jul 2026

Blocking a specific protein improves CAR T-cell therapy success in patients with blood cancers

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

15 Jun 2026